Carlos Jimenez

Surgeon focused in MIS for Bariatrics & Upper GI. National Cancer Center Japan Fellow. European School Of Laparoscopic Surgery Fellow.

[Carlos Jimenez @CarlanJimenez]

Nuestros pacientes merecen todos los tratamientos posibles para esta enfermedad #obesidad desde @inca_cirugia del @HospitaldeInca ofrecemos un programa multidisciplinar que incluye la prehabilitacion en nuestro gimnasio hospitalario @CrossFit.

[Jaime Ponce MD @JaimePonceMD]

JAMA Surgery 2 papers tell an important story:
• Weight loss at 2 yrs: MBS ~28% vs GLP-1s ~10%
• ~10% of MBS pts start GLP-1s by 5 yrs
• GLP-1s cost ~$11K more than MBS at 2 yrs

MBS delivers greater efficacy and value, while reinforcing the need for combination therapy in chronic obesity care.

[JAMA Internal Medicine @JAMAInternalMed]

In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements.

https://t.co/eX8xLaKaS6

[Neil Floch MD @NeilFlochMD]

Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists | JAMA Surgery | JAMA Network #bariatricsurgery #obesity https://t.co/5Jpe5Za811

[Hospital d'Inca @HospitaldeInca]

🏅Categoria Compromís i talent

🏆Curso internacional de postgrado en respuesta médica a incidentes mayores (MRMI) para profesionales de emergencias

👏🏼 Representant del projecte:
Carlo Brugiotti @cbrug76

[Jaime Ponce MD @JaimePonceMD]

Bariatric Surgery vs GLP-1 @JAMASurgery
• 30,458 pts insurance database in the US -2yr f/u
• Bariatric surgery better weight loss
(28.3% vs 10.3%)
• Bariatric Surgery saving $11 689 in ongoing costs
doi: 10.1001/jamasurg.2025.3590
@ASMBS @IfsoSecretariat @IFSO_NAC @frankman1987

[ObesitySEEN @ObesitySeen]

Trajectory of the body weight after drug discontinuation in the treatment of AOMs
La recuperación ponderal es la regla, empezando a las 8 sem, pero sostenida hasta 20 sem. No olvidemos explicar esto al paciente al inicio.
https://t.co/bSToCtLtAe
@sociedadSEEN @SociedadSeedo

[Michael Albert, MD @MichaelAlbertMD]

📉 What REALLY happens when you stop anti‑obesity meds?
- - -
A new meta‑analysis [Wu et al., BMC Medicine, 2025] just mapped the weight regain trajectory after stopping GLP‑1s and other AOMs—and it’s eye‑opening.

Key findings:
⏳ First month off: Weight loss continues briefly (~4 weeks).

📈 By week 8: Regain starts.

🔄 Weeks 8–20: Rapid regain — often 2–3 kg above discontinuation weight.

🪂 After ~6 months: Regain levels off, but most patients keep some net loss vs. baseline.

💉 GLP‑1s hit harder: GLP‑1–based drugs showed the most pronounced regain.

🏋️‍♀️ Lifestyle changes help… but not enough: Even with ongoing diet/exercise programs, regain still occurred.

Why?
🔹Appetite & hunger hormones rebound.
🔹Stomach emptying speeds back up.
🔹Metabolic rate adjusts downward after weight loss.

The takeaway:
Stopping AOMs ≠ “you’re cured.” Obesity is a chronic condition — and without ongoing treatment (whether medication, surgery, or intensive behavioral support), biology will try to pull weight back up.
🔗https://t.co/fP6jHaY91i

[Michael Weintraub, MD @MWeintraubMD]

Real-world comparison of semaglutide/tirzepatide (GLP‑1/GLP‑1+GIP) vs bariatric surgery.

📉 In a real-world matched study of 14,152 pts:
At 2 years:
• Surgery: −25.7% total weight loss (TWL)
• GLP-1s (semaglutide/tirzepatide): −5.3% TWL (ITT); −7.6% (per-protocol)
• HbA1c drop: Surgery −0.5 pts vs GLP-1s −0.2 pts (p<0.001)

⚖️ Conclusion: Surgery delivers greater, sustained weight loss & better glycemic control vs GLP-1s for eligible patients.

https://t.co/64QjVFoZ4J

[Michael Weintraub, MD @MWeintraubMD]

GLP-1RAs were associated with an increased risk of GERD and cholelithiasis but did not significantly increase the risk of pancreatitis, cholecystitis, intestinal obstruction, or other serious gastrointestinal or biliary events.

GLP-1 RAs were associated with increased the risk cholelithiasis (RR [risk ratio], 1.46 [95% CI, 1.09 to 1.97]; two more cases per 1,000) and GERD (RR, 2.19 [95% CI, 1.48 to 3.25]; four more cases per 1,000) compared to placebo

Recent meta analysis of 55 placebo-controlled, randomized controlled trials involving 106,395 participants

https://t.co/cMCgr8mf1w

[Jaime Ponce MD @JaimePonceMD]

Great press on this top paper from my collegues and friends from NYU https://t.co/GGCGa6Sp7i @ASMBS @IfsoSecretariat @IFSO_NAC @nyuniversity @NYULH_Surgery

[EL MUNDO @elmundoes]

Reino Unido detecta un aumento significativo de los casos de pancreatitis asociados al uso de inyecciones como Ozempic o Wegovy para adelgazar https://t.co/Pl6ZiZ5oHZ

[ASMBS @ASMBS]

New Study Shows Weight Loss Surgery to be More Effective Than Medication- Metabolic and bariatric surgery continues to be the most effective treatment for sustained weight loss and long-term health outcomes. https://t.co/pKdnbBugjZ #asmbs #ObesityTreatment #health #obesity

[Michael Albert, MD @MichaelAlbertMD]

🚨 GLP-1s vs Surgery: Who Wins Long Term?
- - -
A new 2-year comparative study from NYU Langone just dropped—and the results are clear:

📊 Bariatric Surgery vs GLP-1s (semaglutide/tirzepatide):
🔹 25.7% total body weight loss with surgery vs 5.3% with GLP-1s (intention-to-treat)
🔹 Even in per-protocol analysis (continuous GLP-1 use), surgery still outperformed: 24.6% vs 7.6%
🔹 Surgery had better HbA1c improvement, too

🔍 Translational Insight:
Yes, the relatively low weight loss in the medication group was partly due to therapy interruptions and discontinuation. But that’s exactly the point:
➡️ If a treatment is regularly interrupted by prior auths, high out-of-pocket costs, or drug shortages, that limits its real-world effectiveness.
➡️ Clinical effectiveness ≠ theoretical efficacy in a vacuum. Access matters.

📌 Bottom line:
For patients with severe obesity (BMI ≥35), bariatric surgery still provides superior long-term outcomes—and it does so reliably, without being derailed by market forces.
Abstract: https://t.co/NlOas6X8j6

[Carlo Brugiotti @cbrug76]

Nuevo Curso MRMI, de 10 a 12 de septiembre en Mallorca

https://t.co/QrEUqayYow

@aecirujanos @StcuaeC @ibsalut @sobacir

[Christian Herrero @ChrisHerreroMD]

Muy contentos tras el primer curso de Cirugía Gástrica Robótica en @parctauli @TauliSurgery de la mano de @abexDaVinci @IntuitiveSurg con alumnos de nivel 🏅🤖🦾 @hggranollers @ConsorciCSI @Cesar_Ginesta @vallhebron @aecirujanos @AEC_CEG .
Con ganas del siguiente 🚀

[Carlo Brugiotti @cbrug76]

Thanks to ECTES 2025 for this kindly invitation. Excited for the new assignment as Secretary of Disaster and Military Surgery section of the European Society of Trauma and Emergency Surgery.
@HospitaldeInca @StcuaeC @aecirujanos @ibsalut @sobacir

[Montse Adell Trapé @MontseAdellT]

Great days in Madrid at the #IBSC2025! Amazing and innovative talks together with live surgeries by the top experts in the field.
Happy to participate talking about “The point of view of early adopters” in robotic bariatric and metabolic surgery
@obesidadSECO

[Jose M. Balibrea MD, PhD, FACS @BalibreaJose]

Disponible en @TheLancetEndo el certificado de defunción de la banda gástrica (QEPD) y la confirmación (otra) de que la gastrectomía vertical es inferior al bypass

@aecirujanos @aec_obesidad @EstebanMAntona @JordiTarasco @SociedadSeedo @ObesitySeen @PelliteroSilvia @juliomayol @recarterico_me @DrCassinello

[Àrea de Salut de Menorca @asmen_ibsalut]

🏥 El servei de Cirurgia de l’Hospital Mateu Orfila es forma en noves competències per a millorar l’atenció als pacients.

👨‍⚕️ Els doctors Alberto Gil i José María García han assistit a un curs de tècnica SADI-S a l’Hospital Universitari de La Plana.

[SEEDO @SociedadSeedo]

📅Hoy, 4 de marzo, conmemoramos el #DíaMundialDeLaObesidad, dando visibilidad a esta enfermedad crónica, recurrente y multifactorial que afecta a millones de personas en todo el mundo.🌎

⚖️La obesidad no es solo un problema de peso, es una enfermedad que impacta todos los aspectos de la salud, afectando órganos y sistemas, y relacionada con más de 200 condiciones, como diabetes tipo 2, enfermedades cardiovasculares, hígado graso y varios tipos de cáncer.

🇪🇸En España, la atención sanitaria para la obesidad es insuficiente, desigual y, en muchos casos, ineficaz. Las personas que viven con obesidad enfrentan barreras diarias, discriminación y, lamentablemente, a menudo no encuentran el apoyo que necesitan.

Vivir con #obesidad es mucho más que un desafío físico; implica una enorme carga psicológica y un estigma social que también se refleja en el sistema de salud. Es hora de que la obesidad sea reconocida como lo que es: una enfermedad crónica que requiere un enfoque integral y multidisciplinario.

💪🏻Ayúdanos a visibilizar el impacto de la obesidad compartiendo este post. ¡Juntos podemos marcar la diferencia! @AlianzaObesidad
#ObesidadEsEnfermedad #LaAlianzaPorLaObesidad #DíaMundialDeLaObesidad #Obesidad #Salud